This study provides critical clinical evidence for switching severe asthma patients from short-acting IL-5–targeted biologics to the long-acting depemokimab, supporting a treatment strategy that reduces dosing frequency while maintaining disease control, with direct implications for adherence and long-term treatment patterns in asthma management.
Literature Overview
The article titled 'Switching to twice-yearly depemokimab from mepolizumab/benralizumab in severe asthma: a multicenter, randomized, double-blind, phase 3A clinical trial (NIMBLE)', published in the American Journal of Respiratory and Critical Care Medicine, systematically investigates the efficacy and safety of switching to subcutaneous depemokimab every six months in patients with severe asthma who have clinically responded to mepolizumab or benralizumab. The study employs a multicenter, randomized, double-blind, dual-placebo controlled design, aiming to assess the non-inferiority of depemokimab as a switch therapy, thereby filling a critical evidence gap in real-world biologic switching strategies.Background Knowledge
Severe asthma affects millions globally, with a subset of patients continuing to experience frequent exacerbations despite high-dose inhaled corticosteroids (ICS) and long-acting β2-agonists (LABA), often requiring oral corticosteroids (OCS) that carry significant side effects. Approximately 80% of severe asthma cases involve type 2 inflammation, driven primarily by IL-4, IL-5, and IL-13. IL-5, in particular, is a key cytokine regulating eosinophil proliferation, activation, and survival, making it a pivotal therapeutic target in severe eosinophilic asthma. Currently approved anti–IL-5 biologics include mepolizumab (anti–IL-5 monoclonal antibody), reslizumab (anti–IL-5 monoclonal antibody), and benralizumab (anti–IL-5Rα monoclonal antibody), all requiring administration every 4 to 8 weeks—posing a substantial treatment burden that affects patient adherence and persistence. While these agents significantly reduce exacerbation rates and OCS use, frequent injections limit the sustainability of long-term therapy. Thus, there is a pressing clinical need for long-acting biologics that reduce dosing frequency and improve adherence. Depemokimab, the first ultra-long-acting anti–IL-5 monoclonal antibody, achieves dosing only twice per year due to its high affinity and extended half-life, and has demonstrated superiority over placebo in the SWIFT-1 and SWIFT-2 trials. However, no randomized controlled data have previously guided the switch from existing biologics to depemokimab in patients already benefiting from them. The NIMBLE study was designed precisely to evaluate the feasibility and safety of such a switch, addressing a key bottleneck in clinical practice as switching needs grow.
Research Methods and Experiments
The study used a multicenter, randomized, double-blind, dual-placebo, parallel-group, phase 3A non-inferiority design (NCT04718389), enrolling patients aged ≥12 years with severe asthma who had been stable for ≥12 months on mepolizumab (100 mg/4 weeks) or benralizumab (30 mg/8 weeks) with clear clinical benefit (e.g., ≥50% reduction in exacerbations, ≥50% OCS reduction, or no exacerbations with ACQ-5 ≤1.5). A total of 1,687 patients were randomized 1:1 to receive depemokimab (100 mg/26 weeks) or remain on their original therapy (mepolizumab or benralizumab), with all patients continuing standard background treatment. The primary endpoint was the annualized rate of clinically significant exacerbations over 52 weeks, with a pre-specified non-inferiority margin of 1.28. Key analyses included negative binomial regression modeling for annualized exacerbation rates, with adjustment for baseline exacerbation history and biologic type; secondary endpoints included SGRQ, ACQ-5, and FEV1 as measures of quality of life and lung function. Pharmacodynamic effects were monitored via dynamic blood eosinophil counts, and safety was assessed through adverse events (AEs), serious adverse events (SAEs), and immunogenicity.Key Conclusions and Perspectives
Research Significance and Prospects
This study is the first randomized controlled trial of biologic switching in severe asthma, marking a shift from an 'initial therapy' to a 'dynamic management' paradigm. Although statistical non-inferiority was not met, the extremely low absolute exacerbation rates and stable functional outcomes indicate that most patients can safely transition to twice-yearly depemokimab, significantly reducing treatment burden. This has major clinical implications for improving long-term adherence and persistence, especially in resource-limited settings or for patients preferring fewer injections. Future research should explore the predictive value of biomarkers (e.g., baseline eosinophils, FeNO) for switch response, as well as long-term OCS cumulative exposure and lung function trajectories with extended follow-up.
Conclusion
This study provides important evidence-based guidance for biologic management in severe asthma. Although depemokimab did not meet the statistical non-inferiority criterion, it demonstrated very low exacerbation rates and stable symptom control in real-world settings, indicating that switching from mepolizumab or benralizumab to twice-yearly depemokimab is a safe and feasible strategy. Notably, for patients originally on mepolizumab, disease control after switching was comparable to continuing the original therapy, supporting depemokimab as an ideal option for reducing dosing frequency. While the group switching from benralizumab showed a slight worsening trend, possibly due to mechanistic differences, the overall risk remains very low. The study underscores the importance of individualized switching strategies, suggesting clinicians consider prior treatment response, eosinophil dynamics, and patient preferences when making decisions. In the long term, depemokimab has the potential to become a key tool for sustaining disease control, improving quality of life, and reducing treatment burden, advancing asthma management toward a more sustainable, patient-centered model and offering a new foundational option for asthma care systems.
